Denise Moore
Acute Care · Springfield, MONPI 1790098580
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $977 of the $1,109 with a category attached, or 88.1%. 24 manufacturers reported payments, led by Bristol Myers Squibb at 25.9% of the total. 2025 is the largest year on record at $366, 2.8 times the $129 reported in 2021.
Across 60 payments — averaging $18.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bristol Myers Squibb$287
- Lilly USA, LLC$106
- Gilead$84
- Novartis$79
- AbbVie$77
- E.r. Squibb & Sons, L.L.C.$60
- plus $416 from 18 others
What the payments were for
- Food & beverage$97788%
- Education$13212%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bristol Myers Squibb | 18 | $287 |
| Lilly USA, LLC | 1 | $106 |
| Gilead(2 entities) | 5 | $84 |
| Novartis | 3 | $79 |
| AbbVie | 5 | $77 |
| E.r. Squibb & Sons, L.L.C. | 4 | $60 |
| GSK | 2 | $46 |
| EMD Serono, Inc. | 2 | $43 |
| AstraZeneca | 2 | $40 |
| Jazz Pharmaceuticals Inc. | 2 | $34 |
| Pfizer | 2 | $34 |
| Acrotech Biopharma Inc. | 2 | $26 |
| Daiichi Sankyo Inc. | 1 | $25 |
| Taiho Oncology, Inc. | 1 | $21 |
| Johnson & Johnson | 1 | $20 |
| Beigene USA, Inc. | 1 | $16 |
| Pharmacosmos Therapeutics Inc. | 1 | $16 |
| Novo Nordisk | 1 | $16 |
| Dova Pharmaceuticals | 1 | $15 |
| Amgen | 1 | $15 |
| Springworks Therapeutics, Inc. | 1 | $14 |
| Regeneron Healthcare Solutions, Inc. | 1 | $14 |
| Merck | 1 | $12 |
| Blueprint Medicines Corporation | 1 | $11 |
How this compares
$1,109 in reported general payments places this provider in the 75th percentile of 272 acute care providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CholestyramineCholestyramine (With Sugar) | 11 | $736 |
| Anastrozole | 31 | $561 |
| Letrozole | 35 | $301 |
| Potassium Chloride | 18 | $278 |
| Prochlorperazine Maleate | 15 | $178 |
| Ondansetron Hcl | 26 | $158 |
| Ciprofloxacin Hcl | 17 | $116 |
| Hydroxyurea | 13 | $94 |
| Alendronate Sodium | 15 | $94 |
| Famotidine | 15 | $78 |
| Cephalexin | 11 | $50 |
| Prednisone | 18 | $49 |
Paid to pharmacies, not to this prescriber.
Other acute care in Springfield
- Rebekah PierceSpringfield$3K
- Lauren ArgoSpringfield$3K
- Melody RussellSpringfield$2K
- Stephanie FranklinSpringfield$2K
- Andria OrtizSpringfield$2K
- Heather DearingSpringfield$1K
- Hanna KlineSpringfield$1K
- Molly CahillKansas City$22K
- Kristin PressChesterfield$14K
- Sarah HeaveyKansas City$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.